Hospital Universitari General de Catalunya Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2009
NCT01393769
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Plan of Industrial Doctorates, AGAUR, Generalitat de Catalunya

Active Ingredients

Drugs in Phase 4 Trials (1)

aflibercept (zaltrap) (1 trial)

Drugs in Phase 2 Trials (1)

melphalan (alkeran) (1 trial)

Drugs in Other Trials (1)

nalmefene (revex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 4)

Retinoblastoma (Phase 2)

Wet Macular Degeneration (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3